KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Regeneron Pharmaceuticals (REGN) Tax Provisions: 2009-2024

Historic Tax Provisions for Regeneron Pharmaceuticals (REGN) over the last 15 years, with Dec 2024 value amounting to $367.3 million.

  • Regeneron Pharmaceuticals' Tax Provisions rose 99.02% to $303.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $567.1 million, marking a year-over-year increase of 80.09%. This contributed to the annual value of $367.3 million for FY2024, which is 49.49% up from last year.
  • Latest data reveals that Regeneron Pharmaceuticals reported Tax Provisions of $367.3 million as of FY2024, which was up 49.49% from $245.7 million recorded in FY2023.
  • Regeneron Pharmaceuticals' Tax Provisions' 5-year high stood at $1.3 billion during FY2021, with a 5-year trough of $245.7 million in FY2023.
  • Moreover, its 3-year median value for Tax Provisions was $367.3 million (2024), whereas its average is $377.8 million.
  • Its Tax Provisions has fluctuated over the past 5 years, first surged by 320.76% in 2021, then tumbled by 58.38% in 2022.
  • Yearly analysis of 5 years shows Regeneron Pharmaceuticals' Tax Provisions stood at $297.2 million in 2020, then spiked by 320.76% to $1.3 billion in 2021, then crashed by 58.38% to $520.4 million in 2022, then crashed by 52.79% to $245.7 million in 2023, then soared by 49.49% to $367.3 million in 2024.